Umedica Laboratories Private Limited Indomethacin Export Data — India (DGFT 2022–2026)

Name: Umedica Laboratories Private Limited Indomethacin Export Records India — #11 Exporter, 4 Shipments, $91.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Indomethacin

India Pharmaceutical Trade Intelligence

$9.4M139 Suppliers70 CountriesHS 30049099

ExportsIndia → UNITED STATES68.0%India → CANADA4.3%

ImportsUNITED STATES → India$205.8K CANADA → India$68.6K

#1 Supplier: HETERO LABS #1 Buyer: GLENMARK PHARMACEUTICALS

Umedica Laboratories Private Limited — Indomethacin Exporter #11 | $91.6K Trade Value | TransData Nexus | TransData Nexus

Umedica Laboratories Private Limited — Indomethacin Exporter Profile

Indian Pharmaceutical Exporter · #11 for Indomethacin · $91.6K export value · DGFT Verified

Umedica Laboratories Private Limited is the #11 Indian exporter of Indomethacin with $91.6K in export value and 4 verified shipments. Umedica Laboratories Private Limited holds a 1.0% market share in Indomethacin exports across 3 countries. The company exports 11 pharmaceutical products worth $32.2M across 8 therapeutic categories.

Umedica Laboratories Private Limited — Indomethacin Export Profile: Buyers & Destinations

Umedica Laboratories Private Limited Indomethacin export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Indomethacin?

Country	Value	Shipments	Share
UNITED STATES	$6.4M	246	73.1%
CANADA	$405.8K	19	4.6%
UGANDA	$305.3K	26	3.5%
CHILE	$268.6K	8	3.1%

Who Are the Top Buyers of Indomethacin from India?

Buyer	Country	Value	Orders
GLENMARK PHARMACEUTICALS INC USA	UNITED STATES	$1.1M	43
EVERSANA LIFE SCIENCE SERVICES	UNITED STATES	$850.0K	17
GLENMARK PHARMACEUTICALS INC., USA	UNITED STATES	$796.0K	44
GLENMARK PHARMACEUTICALS INC, USA	UNITED STATES	$174.2K	8
M S TO THE ORDER OF MINT PHARMACEUTICALS	CANADA	$161.2K	4
MINT PHARMACEUTICALS INC.	CANADA	$132.4K	6
SEVEN PHARMA CHILE SPA	CHILE	$100.0K	2
ESVEE MEDICARE LTD.	ZAMBIA	$84.1K	7
GLENMARK PHARMACEUTICALS INC	UNITED STATES	$81.9K	2
ZEE PHARMACEUTICALS LTD.	UGANDA	$69.8K	8

India's Indomethacin is purchased by 242 buyers worldwide. The top buyer is GLENMARK PHARMACEUTICALS INC USA (UNITED STATES), followed by EVERSANA LIFE SCIENCE SERVICES and GLENMARK PHARMACEUTICALS INC., USA.

How Does Umedica Laboratories Private Limited Compare to Nearest Indomethacin Exporters?

Exporters ranked immediately above and below #11 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
9	SCOTT EDIL PHARMACIA LIMITED	$154.1K	10	3	$15.4K
10	AFRICURE PHARMACEUTICALS (INDIA) PRIVATELIMITED	$102.5K	11	3	$9.3K
11	UMEDICA LABORATORIES PRIVATE LIMITED ★	$91.6K	4	3	$22.9K
12	DEN MARK PHARMACEUTICALS PRIVATE LIMITED	$88.8K	8	1	$11.1K
13	USAN PHARMACEUTICALS PRIVATE LIMITED	$80.5K	4	1	$20.1K

Umedica Laboratories Private Limited ranks #11 among 139 Indian Indomethacin exporters. Average shipment value of $22.9K compared to the market average of $60.6K. The closest competitors by value are SCOTT EDIL PHARMACIA LIMITED and AFRICURE PHARMACEUTICALS (INDIA) PRIVATELIMITED.

Which Indian Ports Ship Indomethacin Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	173	13.9%
SAHAR AIR	164	13.1%
SAHAR AIR CARGO ACC (INBOM4)	157	12.6%
DELHI AIR	113	9.1%
NHAVA SHEVA SEA (INNSA1)	92	7.4%
HYDERABAD ICD	66	5.3%
JNPT	53	4.2%
Bombay Air	48	3.8%

Geopolitical & Trade Policy Impact on Umedica Laboratories Private Limited's Indomethacin Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Umedica Laboratories. The Israel-Iran conflict has led to disruptions in Middle East trade routes, particularly affecting the Red Sea shipping lanes. Major shipping lines have imposed 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, effectively increasing the cost of exporting goods through these routes. This escalation in shipping costs can erode profit margins and necessitate strategic adjustments in logistics and pricing strategies. (sgeexport.com)

Conversely, the US-China trade tensions have prompted the United States to seek alternative sources for pharmaceuticals, potentially benefiting Indian exporters. However, the imposition of tariffs on Indian goods by the US, including a 25% tariff announced in 2025, poses a significant challenge. This tariff could lead to increased costs for Indian pharmaceutical products in the US market, potentially affecting demand and profitability. (en.wikipedia.org)

The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a promising avenue for Umedica. The FTA eliminates tariffs on Indian pharmaceutical exports to the EU, providing a competitive advantage and facilitating market expansion. This agreement is expected to open a market worth $572.3 billion for Indian pharmaceutical and MedTech exports to Europe from 2027 onward. (mordorintelligence.com)

Umedica Laboratories Private Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent Good Manufacturing Practice (GMP) requirements. Historically, non-compliance has led to import bans and reputational damage for Indian firms. For instance, in 2013, the FDA banned imports from certain Indian pharmaceutical companies due to GMP violations, highlighting the critical importance of adherence to quality standards. (comcec.org)

While specific regulatory events concerning Umedica Laboratories are not detailed in the available data, the company's sustained export performance suggests a commitment to maintaining high-quality standards and compliance with international regulations. Continuous investment in quality control systems and regulatory compliance is essential to navigate the evolving landscape and to capitalize on global market opportunities.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Indomethacin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Umedica Laboratories Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 70+ countries, 242+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Indomethacin

Indomethacin

Umedica Laboratories Private Limited — Indomethacin Exporter Profile

Umedica Laboratories Private Limited — Indomethacin Export Profile: Buyers & Destinations

Where Does India Export Indomethacin?

Who Are the Top Buyers of Indomethacin from India?

What Is India's Total Indomethacin Export Value and How Much Does Umedica Laboratories Private Limited Contribute?

What Is the Average Shipment Value for Umedica Laboratories Private Limited's Indomethacin Exports?

How Does Umedica Laboratories Private Limited Compare to Other Indian Indomethacin Exporters?

Regulatory Requirements: Exporting Indomethacin to Key Markets

United States — FDA

Canada — HC

How Does Umedica Laboratories Private Limited Compare to Nearest Indomethacin Exporters?

Which Indian Ports Ship Indomethacin Exports?

What Other Analgesics & Antipyretics Products Does Umedica Laboratories Private Limited Export?

Geopolitical & Trade Policy Impact on Umedica Laboratories Private Limited's Indomethacin Exports

Umedica Laboratories Private Limited — Regulatory Compliance & Quality Standards

About Umedica Laboratories Private Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Indomethacin Export Data from Umedica Laboratories Private Limited

Indomethacin Stats

Company Overview

Top Products by Umedica Laboratories Private Limited

Related Analysis

Need Detailed Export Data?

Data Source